NASHVILLE, Tenn.--(BUSINESS WIRE)--The Sarah Cannon Blood Cancer Network announced today that 24 abstracts have been accepted for presentation at the 2016 BMT Tandem Meetings held Feb. 18 – 22. The presentations, which represent clinicians from its network of blood and marrow transplant (BMT) programs across the United States, focus on quality improvement, pathways, efficacy and treatment standards of blood and marrow transplantation for various blood disorders.
Members of the Sarah Cannon Blood Cancer Network comprise a multidisciplinary team of physicians and staff from seven FACT accredited blood cancer programs. Programs presenting at the 2016 BMT Tandem meetings include Texas Transplant Institute, Colorado Blood Cancer Institute, OU Medical Center, Medical City Dallas Hospital, and four presentations from Sarah Cannon Blood Cancer Network leadership.
“The abstracts highlight research focused on creating best-in-class processes and pathways for blood and marrow transplantation,” said Fred LeMaistre, MD physician in chief of blood cancers for Sarah Cannon. “Given our network’s experience in performing more than 12,000 transplants, we bring together a variety of insights that have helped to shape our strategies for advancing care standards for patients.”
One of the noteworthy abstracts to be presented is the Sarah Cannon Blood Cancer Network’s Oncology Alert program pilot that has been deployed in multiple network emergency departments across the U.S. The unique program seeks to reduce the door to antibiotic time in emergency departments for patients with febrile neutropenia. Published data from U.S. and international sites demonstrates the median time for febrile neutropenic oncology patients is 102 – 300 minutes. Sarah Cannon’s Oncology Alert program has demonstrated significant improvements in patient care for this population by reducing the median time to 52 minutes.
“Patients with febrile neutropenia, a condition marked by fever due to low white blood cells, need emergent attention and rapid antibiotic intervention. These patients are extremely susceptible to infections due to their compromised immune systems,” said Paul Shaughnessy, MD, Program Medical Director at Texas Transplant Institute, a Sarah Cannon Blood Cancer Network member. “We have used the Oncology Alert program for the last four years and have seen dramatic improvements, resulting in better care and ultimately better outcomes for this vulnerable patient population.”
The combined annual meetings of the American Society for Blood and Marrow Transplantation (ASBMT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) bring together thousands of physicians, investigators, clinicians and other healthcare professionals to discuss blood and marrow transplantation, research, education and clinical standards. For more information about Sarah Cannon’s presence at the meetings, visit sarahcannon.com/BMTtandem.
The Sarah Cannon Blood Cancer Network is one of the largest providers of blood and marrow transplantation conducting approximately 1,000 transplants annually through seven FACT accredited transplant centers and approximately 12,000 transplants since the inception of its first program. Through its commitment to the highest level of quality standards, infrastructure, technology, training and research, the Sarah Cannon Blood Cancer Network provides an unparalleled experience for patients seeking treatment.
About The Sarah Cannon Blood Cancer Network
Sarah Cannon brings together physician-led blood cancer programs across the United States and United Kingdom to offer patients convenient access to care including blood and marrow transplants and clinical trials. Sarah Cannon Blood Cancer Network programs include St. David’s South Austin Medical Center in Austin, TX, Medical City Dallas Hospital in Dallas, TX, Colorado Blood Cancer Institute at Presbyterian/St. Luke’s Medical Center - HealthONE in Denver, Colo., HCA Midwest Health - Research Medical Center, in Kansas City, Mo., Sarah Cannon Center for Blood Cancer at TriStar Centennial Medical Center in Nashville, Tenn., Tulane Medical Center in New Orleans, La., OU Medical Center in Oklahoma City, Okla., Texas Transplant Institute at Methodist Hospital in San Antonio, TX, Harley Street at University College Hospital in London and The Christie Clinic in Manchester, England. For more information about the Blood Cancer Network and Sarah Cannon’s full suite of oncology services, visit sarahcannon.com.